{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.4","upperLimit":"54.9","value":"36.4"}]}],"title":"By cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"28.1","upperLimit":"63.6","value":"45.5"}]}],"title":"By cycle 6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"33.5","upperLimit":"69.2","value":"51.5"}]}],"title":"By cycle 9"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39.2","upperLimit":"74.5","value":"57.6"}]}],"title":"By cycle 12"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39.2","upperLimit":"74.5","value":"57.6"}]}],"title":"By cycle 18"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39.2","upperLimit":"74.5","value":"57.6"}]}],"title":"By cycle 24"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39.2","upperLimit":"74.5","value":"57.6"}]}],"title":"By cycle 36"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"42.1","upperLimit":"77.1","value":"60.6"}]}],"title":"By cycle 48"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"42.1","upperLimit":"77.1","value":"60.6"}]}],"title":"By cycle 66"}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"Major molecular response (MMR) was defined as BCR-ABL/ABL % ≤ 0.1% by IS as measured by RQ-PCR, confirmed by duplicate analysis of the same sample.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients resistant or intolerant to either imatinib or dasatinib","id":"OG000","title":"Resistant/Intolerant Ph+ CML in CP"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS): All patients who received at least one dose of study medication","reportingStatus":"POSTED","timeFrame":"By 3, 6, 9 , 12, 24, 36, 48, 66 cycles ( 1 cycle = 28 days)","title":"MMR Rate by Time Points in Ph+ CML-CP Patients Resistant or Intolerant to Imatinib or Dasatinib","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}